Drug intelligence / Profile preview

gemibotulinumtoxinA

Development stage: Phase 2
Lead developer: AbbVie
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular Injection

Overview

gemibotulinumtoxinA (AGN-151607-DP) is an investigational drug developed by AbbVie. It is a botulinum toxin type A being studied for its safety and efficacy in facilitating primary fascial closure without the use of component separation technique in subjects undergoing open abdominal ventral hernia repair. The drug works by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation.

Other names: gemibotulinumtoxinA-DP

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on gemibotulinumtoxinA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemibotulinumtoxinA.

Explore the full profile